American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

Mekinian, AM.; Georgin-Lavaille, S.; Ferrada, MA.; Savic, S.; Koster, MJ.; Kosmider, O.; Comont, T.; Heilblig, M.; Arostegui, JI.; Bosco, A.; Bourguiba, R.; Calvo, KR.; Cargo, C.; Cattaneo, C.; Chasset, F.; Coelho, H.; Campochiaro, C.; Crisafulli, F.; Ducharme-Benard, S.; Faria, R.; Franceschini, F.; Frassi, M.; Groarke, EM.; Gurnari, C.; Hakobyan, Y.; Jamilloux, Y.; Jurcut, C.; Kirino, Y.; Kulasekararaj, A.; Kunimoto, H.; Madigan, LM.; Mann, HF.; Marvisi, C.; Milchert, M.; Morais, S.; Sockel, K.; Muratore, F.; Nakajima, H.; Patnaik, MM.; Regadas, L.; Robin, M.; Rutgers, A.; Salvarani, C.; Sammel, AM.; Seebach, J.; Sujobert, P.; Tomelleri, A.; Urbanski, G.; Vandergheynst, F.; Vieira, R.; Viswanatha, DS.; Wiesik-Szewczyk, E.; Diral, E.; Terrier, B.; Patel, BA.; Fenaux, P.; Grayson, PC.; Beck, DB.

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.

All Authors

Mekinian, AM.

Georgin-Lavaille, S.

Ferrada, MA.

Savic, S.

Koster, MJ.

Kosmider, O.

Comont, T.

Heilblig, M.

Arostegui, JI.

Bosco, A.

Show 10 more

LTHT Author

Savic, Louise
Cargo, Catherine

LTHT Department

Theatres & Anaesthetics
Anaesthetics
Oncology
Haematology
Haematological Malignancy Diagnostic Service

Publication Date

2025

Item Type

Journal Article

Abstract

OBJECTIVE: Vacuoles E1 enzyme X-linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. METHODS: Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. RESULTS: Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. CONCLUSION: This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.